https://ipharmag.com/article/lilly-retatrutide-black-market-lawsuits iPharmag en 2026-08-13T05:57:59+00:00 Lilly Sues Six Sellers to Shut Down a ‘Black Market’ for Its Unapproved Weight-Loss Drug https://ipharmag.com/article/glp1-lateral-septum-brain-craving-center iPharmag en 2026-08-13T05:57:59+00:00 GLP-1 Drugs May Curb Cravings Through a Little-Known Brain ‘Craving Center’ https://ipharmag.com/article/drc-ebola-vaccine-trial-who-outbreak iPharmag en 2026-08-13T05:57:59+00:00 WHO Advances Plans for an Ebola Vaccine Trial as a DRC Outbreak Surges https://ipharmag.com/article/definium-lsd-pill-anxiety-phase3 iPharmag en 2026-08-13T05:57:59+00:00 A Pharmaceutical LSD Pill Posted Positive Phase 3 Data for Anxiety https://ipharmag.com/article/boulevard-bio-launch-schett-immune-reset iPharmag en 2026-08-13T05:57:59+00:00 Boulevard Bio Launches With $65M to Chase ‘Immune Reset’ Drugs for Autoimmune Disease https://ipharmag.com/article/stopping-statins-over-75-low-risk-study iPharmag en 2026-08-12T00:31:28+00:00 Stopping Statins After 75 Didn’t Raise Deaths in Low-Risk Older Adults, Trial Finds https://ipharmag.com/article/k2-therapeutics-ying-huang-china-drug-licensing iPharmag en 2026-08-12T00:31:28+00:00 Ex-Legend CEO Ying Huang Takes Over a Startup Scouring the Globe — Especially China — for Drugs https://ipharmag.com/article/fresenius-kabi-tyenne-tocilizumab-recall-glass iPharmag en 2026-08-12T00:31:28+00:00 Fresenius Kabi Recalls a Lot of Its Arthritis Biosimilar Tyenne Over Glass Particles https://ipharmag.com/article/dexamethasone-lung-inflammation-immune-defense iPharmag en 2026-08-12T00:31:28+00:00 A Common Steroid Calmed Chronic Lung Inflammation Without Disarming Immune Defenses https://ipharmag.com/article/beone-revolution-medicines-ras-oncology-partnership iPharmag en 2026-08-12T00:31:28+00:00 BeOne and Revolution Medicines Team Up on RAS-Driven Cancer Combinations https://ipharmag.com/article/spatial-transcriptomics-heart-transplant-rejection iPharmag en 2026-08-11T04:37:23+00:00 Mapping Heart-Transplant Rejection Cell by Cell Reveals Hidden Differences https://ipharmag.com/article/sobi-innate-lacutamab-ctcl-licensing-deal iPharmag en 2026-08-11T04:37:23+00:00 Sobi Licenses Innate’s Skin-Lymphoma Drug in a Deal Worth Up to $580M https://ipharmag.com/article/jazz-actio-biosciences-kcnt1-epilepsy-acquisition iPharmag en 2026-08-11T04:37:23+00:00 Jazz to Buy Actio Biosciences for $820M, Betting on a Rare Genetic Epilepsy https://ipharmag.com/article/bms-houston-2-3-billion-manufacturing-campus iPharmag en 2026-08-11T04:37:23+00:00 Bristol Myers Squibb to Build a $2.3 Billion Drug-Manufacturing Campus in Houston https://ipharmag.com/article/aleniglipron-oral-glp1-pill-weight-loss iPharmag en 2026-08-11T04:37:23+00:00 An Experimental GLP-1 Pill Delivered Up to 12% Weight Loss in a Mid-Stage Trial